Artículos por temáticas

Neuroprotective Mechanisms of Three Natural Antioxidants on a Rat Model of Parkinson's Disease: A Comparative Study

Tancheva LP, Lazarova MI, Alexandrova AV, Dragomanova ST, Nicoletti F, Tzvetanova ER, Hodzhev YK, Kalfin RE, Miteva SA, Mazzon E, Tzvetkov NT, Atanasov AG.

Antioxidants (Basel). 2020 Jan 6;9(1):49. doi: 10.3390/antiox9010049.

Maladaptive avoidance patterns in Parkinson's disease are exacerbated by symptoms of depression

Sheynin J, Baetu I, Collins-Praino LE, Myers CE, Winwood-Smith R, Moustafa AA.

Behav Brain Res. 2020 Mar 16;382:112473. doi: 10.1016/j.bbr.2020.112473. Epub 2020 Jan 11.

Implicit task switching in Parkinson's disease is preserved when on medication

Yaffe JA, Zlotnik Y, Ifergane G, Levy-Tzedek S.

PLoS One. 2020 Jan 14;15(1):e0227555. doi: 10.1371/journal.pone.0227555. eCollection 2020.

Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease

Harris JP, Burrell JC, Struzyna LA, Chen HI, Serruya MD, Wolf JA, Duda JE, Cullen DK.

NPJ Parkinsons Dis. 2020 Jan 8;6:4. doi: 10.1038/s41531-019-0105-5. eCollection 2020.

Dementia in long-term Parkinson's disease patients: a multicentre retrospective study

Szeto JYY, Walton CC, Rizos A, Martinez-Martin P, Halliday GM, Naismith SL, Chaudhuri KR, Lewis SJG.

NPJ Parkinsons Dis. 2020 Jan 7;6:2. doi: 10.1038/s41531-019-0106-4. eCollection 2020.

Potential of animal models for advancing the understanding and treatment of pain in Parkinson's disease

Buhidma Y, Rukavina K, Chaudhuri KR, Duty S.

NPJ Parkinsons Dis. 2020 Jan 6;6:1. doi: 10.1038/s41531-019-0104-6. eCollection 2020.

Impact of Maternal Separation on Dopamine System and its Association with Parkinson's Disease

He KJ, Zhang YT, Wei SZ, Jiang SM, Xu L, Ren C, Wang F.

Neuromolecular Med. 2020 Sep;22(3):335-340. doi: 10.1007/s12017-019-08587-x. Epub 2020 Jan 13.

Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson's disease

Ng ASL, Tan YJ, Lu Z, Ng EY, Ng SYE, Chia NSY, Setiawan F, Xu Z, Keong NCH, Tay KY, Au WL, Tan LCS, Tan EK.

Aging (Albany NY). 2020 Jan 13;12(2):1488-1495. doi: 10.18632/aging.102695. Epub 2020 Jan 13.

Serotonergic Degeneration in Parkinson's Disease: What Is the Link With the Age of Onset?

Macerollo A.

Can J Neurol Sci. 2020 May;47(3):287-288. doi: 10.1017/cjn.2020.11.

Regulation of immune-driven pathogenesis in Parkinson's disease by gut microbiota

Zheng W, He R, Yan Z, Huang Y, Huang W, Cai Z, Su Y, Liu S, Deng Y, Wang Q, Xie H.

Brain Behav Immun. 2020 Jul;87:890-897. doi: 10.1016/j.bbi.2020.01.009. Epub 2020 Jan 10.

Anti-inflammatory effects of usnic acid in an MPTP-induced mouse model of Parkinson's disease

Lee S, Lee Y, Ha S, Chung HY, Kim H, Hur JS, Lee J.

Brain Res. 2020 Mar 1;1730:146642. doi: 10.1016/j.brainres.2019.146642. Epub 2020 Jan 10.

Subthalamic Nucleus Stimulation Impairs Motivation: Implication for Apathy in Parkinson's Disease

Vachez Y, Carcenac C, Magnard R, Kerkerian-Le Goff L, Salin P, Savasta M, Carnicella S, Boulet S.

Mov Disord. 2020 Apr;35(4):616-628. doi: 10.1002/mds.27953. Epub 2020 Jan 13.

CLU rs11136000 promotes early cognitive decline in Parkinson's disease

Sampedro F, Marín-Lahoz J, Martínez-Horta S, Pérez-González R, Pagonabarraga J, Kulisevsky J.

Mov Disord. 2020 Mar;35(3):508-513. doi: 10.1002/mds.27949. Epub 2020 Jan 13.

Modified level of miR-376a is associated with Parkinson's disease

Baghi M, Rostamian Delavar M, Yadegari E, Peymani M, Pozo D, Hossein Nasr-Esfahani M, Ghaedi K.

J Cell Mol Med. 2020 Feb;24(4):2622-2634. doi: 10.1111/jcmm.14979. Epub 2020 Jan 12.

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease

Tanner CM, Pahwa R, Hauser RA, Oertel WH, Isaacson SH, Jankovic J, Johnson R, Chernick D, Hubble J.

J Parkinsons Dis. 2020;10(2):543-558. doi: 10.3233/JPD-191841.